ClinicalTrials.gg
RecruitingNCT07344649Updated Apr 15, 2026

Turkish Validation of the Nijmegen Questionnaire in COPD

An observational study in COPD, sponsored by Saglik Bilimleri Universitesi. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Saglik Bilimleri Universitesi · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey — 58 open to participants now, 68 under way, 7 of them phase 3. Pulmonary Disease, Chronic Obstructive · Turkey.

Planned enrollment
28th of 60
90 · median 77
Started
2026
with 15 others
Observational
60 of 248
19 open now
Primary completion
2027-01
later than 55 of 67 live
Registered
229th of 248
by date
Lead sponsor
9 of 248
Saglik Bilimleri Universitesi

Among the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, this one is the 28th largest by planned enrollment of the 60 observational ones that give a count, is one of 16 that started in 2026, is one of 60 observational ones, reaches primary completion later than 55 of the 67 other live ones, and was the 229th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

58 of the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey are open now. Recruiting first, the newest first:

52 more — sign in →

All 58 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, or all of them as a file.
02

Study summary

Dysfunctional breathing is a common and clinically relevant problem in patients with chronic obstructive pulmonary disease (COPD), contributing to increased dyspnea perception, reduced exercise tolerance, and impaired quality of life. The Nijmegen Questionnaire (NQ) is a widely used symptom-based instrument for screening dysfunctional breathing; however, a validated Turkish version for patients with COPD is currently unavailable.

This observational methodological study aims to translate, culturally adapt, and evaluate the validity and reliability of the Turkish version of the Nijmegen Questionnaire (NQ-TR) in individuals with stable COPD.

Read the detailed description

This single-center observational study will be conducted in patients with clinically stable COPD. The study consists of two main phases: (1) translation and cultural adaptation of the Nijmegen Questionnaire following international guidelines for patient-reported outcome measures, and (2) psychometric evaluation of the Turkish version in a COPD population.

The translation process includes forward translation, reconciliation, back-translation, developer review, cognitive debriefing with patients, and final proofreading. After completion of the linguistic adaptation, the NQ-TR will be administered to eligible participants at baseline and repeated after one week in clinically stable individuals to assess test-retest reliability.

Construct validity will be evaluated using exploratory and confirmatory factor analyses. Convergent validity will be assessed by examining correlations between NQ-TR scores and established clinical measures, including the COPD Assessment Test (CAT), Modified Medical Research Council (mMRC) Dyspnea Scale, Hospital Anxiety and Depression Scale (HADS), and Dyspnea-12 (D-12). Internal consistency, test-retest reliability, and measurement stability will be analyzed.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population consists of adults aged 18 years and older with a confirmed diagnosis of chronic obstructive pulmonary disease (COPD) according to GOLD criteria. Eligible participants are clinically stable patients attending the pulmonology outpatient clinic of a tertiary care hospital, with no acute exacerbation or hospitalization within the previous four weeks. All participants are Turkish-speaking, able to complete self-reported questionnaires, and provide written informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years and older
  • Diagnosis of confirmed according to GOLD criteria
  • Clinically stable disease (no acute exacerbation or hospitalization within the last 4 weeks)
  • Ability to read and understand Turkish
  • Willingness to participate and provide written

Exclusion criteria

Exclusion Criteria:

  • Acute exacerbation or respiratory infection within the previous 4 weeks
  • Presence of severe cardiac, neurological, or systemic disease affecting questionnaire responses
  • Coexisting pulmonary conditions such as bronchiectasis, lung cancer, prior pulmonary tuberculosis, pleural disease, or history of lung surgery
  • Moderate to severe cognitive impairment or communication difficulties
  • Severe visual or hearing impairment preventing questionnaire completion
  • Pregnancy
  • Refusal to participate or withdrawal during the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • COPD

    Other: Questionnaires

Interventions

  • OtherQuestionnaires

    Administration of validated self-reported questionnaires (Nijmegen Questionnaire, CAT, mMRC, HADS, Dyspnea-12)

06

What researchers measure

Primary outcomes

  1. Turkish version of the Nijmegen Questionnaire (NQ-TR)

    The Nijmegen Questionnaire is a validated self-report instrument used to assess symptoms related to dysfunctional breathing and hyperventilation. It consists of 16 items evaluating the frequency of respiratory and non-respiratory symptoms, with higher total scores indicating greater symptom severity. In this study, the Turkish-validated version of the Nijmegen Questionnaire (NQ-TR) will be used to evaluate dysfunctional breathing symptoms in participants.

    Time frame: Baseline and 1 week

Secondary outcomes

  1. COPD Assessment Test (CAT)

    The COPD Assessment Test (CAT) is a validated, patient-completed questionnaire designed to assess the impact of chronic obstructive pulmonary disease (COPD) on health status. It consists of 8 items covering symptoms, activity limitation, and overall well-being, with total scores ranging from 0 to 40. Higher scores indicate a greater impact of COPD on health status. In this study, the Turkish-validated version of the COPD Assessment Test (CAT) will be used to evaluate disease-related symptom burden and health status in participants with COPD.

    Time frame: Baseline

  2. Modified Medical Research Council (mMRC) Dyspnea Scale

    The Modified Medical Research Council (mMRC) Dyspnea Scale is a widely used, validated scale for assessing the severity of perceived breathlessness related to physical activity in individuals with chronic respiratory diseases. The scale grades dyspnea from 0 to 4, with higher grades indicating greater functional limitation due to breathlessness. In this study, the Turkish-validated version of the Modified Medical Research Council (mMRC) Dyspnea Scale will be used to assess dyspnea severity in participants.

    Time frame: Baseline

  3. Dyspnea-12 (D-12) Scale

    The Dyspnea-12 (D-12) Scale is a validated patient-reported outcome measure designed to assess both the physical and affective components of breathlessness. It consists of 12 items, with total scores ranging from 0 to 36, where higher scores indicate greater dyspnea severity. In this study, the Turkish-validated version of the Dyspnea-12 (D-12) Scale will be used to evaluate the multidimensional severity of dyspnea in participants.

    Time frame: Baseline

  4. Hospital Anxiety and Depression Scale (HADS)

    The Hospital Anxiety and Depression Scale (HADS) is a validated self-report questionnaire designed to assess symptoms of anxiety and depression in individuals with physical health conditions. It consists of 14 items divided into two subscales: anxiety (HADS-A) and depression (HADS-D), each comprising 7 items, with subscale scores ranging from 0 to 21. Higher scores indicate greater psychological distress. In this study, the Turkish-validated version of the Hospital Anxiety and Depression Scale (HADS) will be used to evaluate anxiety and depression levels in participants.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 8 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 8 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 1, 2026
First posted
Jan 15, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07344649
Responsible party
ESRA PEHLIVAN (Principal Investigator, Saglik Bilimleri Universitesi) — Principal investigator
First posted
Jan 15, 2026
Start date
Apr 13, 2026
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Esra Pehlivan
Contact
esra.pehlivan@sbu.edu.tr
0 216 777 8 777
Cahidenur Koçak
Contact
cahidekocak25@gmail.com
0 216 777 8 777

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion